|Day Low/High||188.19 / 194.79|
|52 Wk Low/High||163.31 / 210.19|
Jim discusses Amazon's challenge against freight transportation companies, Apple, why he is excited about a new study from Amgen, CVS Health, Nvidia, and more!
For the month of November RMPIA climbed 1.2% month over month.
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia
Market sentiment has certainly improved from this weekend's events.
The market responded favorably after Fed Chair Jerome Powell portrayed a more dovish stance on interest rates.
THOUSAND OAKS, Calif., Nov.
We bought today what the market sold the hardest such as high-multiple cloud/software technology stocks like Salesforce.com and Palo Alto Networks.
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease
Additional Data Analyzing Treatment Patterns in the United States Shows Underutilization of LDL-C Lowering Treatments in At-Risk Patients and Need for Improved Patient Awareness of Treatment Goals
Investors should continue to hold Amgen.
New Pledge is in Addition to $250,000 Contribution to Ventura County Community Foundation's Conejo Valley Victims Fund
Jim Cramer says the Fed is overreacting and he isn't worried about oil prices. Here's your game plan for next week.
Markets had another volatile week as trade tensions crossed currents with a U.S. midterm election that was closer than many had predicted.
Jim discusses Aimovig and Amgen, Anadarko and Schlumberger, the Federal Reserve, Disney ahead of earnings, and more!
We think defense stocks, among other sectors, can rally.
A split Congress is the best-case scenario for the drug industry, several analysts said.
Additional Analyses of Real-World Data Will Explore Treatment Utilization and Understanding of Treatment Goals in Patients at High Risk for Cardiovascular Events
Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
Jim Cramer takes a look at Microsoft, Ross Stores, Pitney Bowes, Alnylam Pharmaceuticals, Golar LNG, ResMed and more.
Jim Cramer breaks down the day's roller-coaster action amid confusing news. Plus, he's got your game plan for next week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.